A probiotic strain of escherichia coli, nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice

British Journal of Pharmacology

Volumn 157, Issue 6, 2009, Pages 1024-1033

  Arribas, B ^a   Rodriguez Cabezas M E ^a   Camuesco, D ^a   Comalada, M ^a   Bailon E ^a   Utrilla, P ^a   Nieto, A ^b   Concha, A ^b   Zarzuelo, A ^a   Galvez J ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Cytokines; Escherichia coli Nissle 1917; IgG; Intestinal anti inflammatory activity; Mice LPS septic shock; TNBS rat colitis

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN G; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 5; MYELOPEROXIDASE; NISSLE 1917; PROBIOTIC AGENT; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; BACTERIAL STRAIN; COLITIS; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; FEMALE; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; INFLAMMATORY INFILTRATE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPTIC SHOCK; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; ESCHERICHIA COLI; FEMALE; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; PROBIOTICS; RATS; RATS, WISTAR; SHOCK, SEPTIC;

EID: 70350337980     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00270.x     Document Type: Article

References (47)

1. Altenhoefer A, Oswald S, Sonnenborn U, Enders C, Schulze J, Hacker J et al. (2004). The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol 40: 223-229. (Pubitemid 38368186)
2. Anderson ME (1985). Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 113: 548-555.
3. Annane D, Bellissant E, Cavaillon JM (2005). Septic shock. Lancet 365: 63-78.
4. Arad G, Hillman D, Levy R, Kaempfer R (2004). Broad-spectrum immunity against superantigens is elicited in mice protected from lethal shock by a superantigen antagonist peptide. Immunol Lett 91: 141-145.
5. Ayala A, Lehman DL, Herdon CD, Chaudry IH (1994a). Mechanism of enhanced susceptibility to sepsis following hemorrhage. Interleukin-10 suppression of T-cell response is mediated by eicosanoid-induced interleukin-4 release. Arch Surg 129: 1172-1178.
6. Ayala A, Deol ZK, Lehman DL, Herdon CD, Chaudry IH (1994b). Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/IFN-gamma release while increasing IL-4/ IL-10 production. J Surg Res 56: 579-585.
7. Baharav E, Mor F, Halpern M, Weinberger A (2004). Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J Nutr 134: 1964-1969.
8. Bailón E, Camuesco D, Nieto A, Concha A, Fernández de Arriba A, Román J et al. (2007). The intestinal anti-inflammatory effects of the novel agent UR-1505 in the TNBS model of rat colitis are mediated by T-lymphocyte inhibition. Biochem Pharmacol 74: 1496-1506.
9. Bell CJ, Gall DG, Wallace JL (1995). Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol 268: G622-G630.
10. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N (2001). The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96: 1116-1122.
11. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A (2003). Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 18: 45-56.
12. Camuesco D, Comalada M, Rodriguez-Cabezas ME, Nieto A, Lorente MD, Concha A et al. (2004). The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br J Pharmacol 143: 908-918.
13. Comalada M, Camuesco D, Sierra S, Ballester I, Xaus J, Gálvez J et al. (2005). In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur J Immunol 35: 584-592.
14. Cuzzocrea S, Mazzon E, Di Paola R, Esposito E, Macarthur H, Matus-chak GM et al. (2006). A role for nitric oxide-mediated peroxynitrite formation in a model of endotoxin-induced shock. J Pharmacol Exp Ther 319: 73-81.
15. Damaskos D, Kolios G (2008). Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. Br J Clin Pharmacol 65: 453-467.
16. Fiocchi C (1998). Inflammatory bowel disease: etiology and pathogen-esis. Gastroenterology 115: 182-205.
17. Fric P, Zavoral M (2003). The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 15: 313-315.
18. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J et al. (2006). Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways. Infect Immun 74: 4075-4082.
19. Grozdanov L, Zahringer U, Blum-Oehler G, Brade L, Henne A, Knirel YA et al. (2002). A single-nucleotide exchange in the wzy gene is responsible for the semi-rough O6 LPS phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol 184: 5912-5925.
20. Haveman JW, Muller Kobold AC, Tervaert JW, van den Berg AP, Tulleken JE, Kallenberg CG et al. (1999). The central role of mono-cytes in the pathogenesis of sepsis: consequences for immunomoni-toring and treatment. Neth J Med 55: 132-141.
21. Henker J, Laass MW, Blokhin BM, Maydannik VG, Bolbot YK, Elze M et al. (2008). Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J 27: 494-499.
22. Hockertz S (1997). Augmentation of host defence against bacterial and fungal infections of mice pretreated with the non-pathogenic Escherichia coli strain Nissle 1917. Arzneimittelforschung 47: 793-796.
23. Hotchkiss RS, Karl IE (2003). The pathophysiology and treatment of sepsis. N Engl J Med 348: 138-150.
24. Isolauri E, Arvola T, Sütas Y, Moilanen E, Salminen S (2000). Probiotics in the management of atopic eczema. Clin Exp Allergy 30: 1604-1610.
25. Ito H, Koide N, Hassan F, Islam S, Tumurkhuu G, Mori I et al. (2006). Lethal endotoxic shock using alpha-galactosylceramide sensitiza-tion as a new experimental model of septic shock. Lab Invest 86: 254-261.
26. Kim GY, Roh SI, Park SK, Ahn SC, Oh YH, Lee JD et al. (2003). Alleviation of experimental septic shock in mice by acidic polysac-charide isolated from the medicinal mushroom Phellinus linteus. Biol Pharm Bull 26: 1418-1423.
27. Krawisz JE, Sharon P, Stenson WF (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87: 1344-1350.
28. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M et al. (2004). Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesala-zine. Gut 53: 1617-1623.
29. Lee SK, Kim YW, Chi SG, Joo YS, Kim HJ (2008). The effect of Saccha-romyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Dig Dis Sci 54: 255-263.
30. Leite MS, Pacheco P, Gomes RN, Guedes AT, Castro-Faria-Neto HC, Bozza PT et al. (2005). Mechanisms of increased survival after lipopolysaccharide-induced endotoxic shock in mice consuming olive oil-enriched diet. Shock 23: 173-178.
31. Liu SF, Malik AB (2006). NF-kB activation as a pathological mechanism of septic shock and inflammation. Am J Physiol 290: L622-L645.
32. Morris GP, Beck PL, Herridge W, Depew W, Szewczuk MR, Wallace JL (1989). Hapten induced model of chronic inflammation and ulcer-ation in rat colon. Gastroenterology 96: 795-803.
33. Naito Y, Takagi T, Yoshikawa T (2007). Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease. J Gastroenterol 42: 787-798.
34. Oberholzer A, Oberholzer C, Moldawer LL (2002). Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 30: S58-S63.
35. Peran L, Camuesco D, Comalada M, Nieto A, Concha A, Adrio JL et al. (2006). Lactobacillus fermentum, a probiotic capable to release glu-tathione, prevents colonic inflammation in the TNBS model of rat colitis. Int J Colorectal Dis 21: 737-746.
36. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH et al. (2003). Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 111: 389-395.
37. Sartor RB (2004). Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebi-otics. Gastroenterology 126: 1620-1633.
38. Schultz M (2008). Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 14: 1012-1018.
39. Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeier F, Göttl C et al. (2004). Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 11: 372-378.
40. Sener G, Toklu H, Kapucu C, Ercan F, Erkanli G, Kaçmaz A et al. (2005). Melatonin protects against oxidative organ injury in a rat model of sepsis. Surg Today 35: 52-59. (Pubitemid 40941131)
41. Sheil B, McCarthy J, O'Mahony L, Bennett MW, Ryan P, Fitzgibbon JJ et al. (2004). Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 53: 694-700.
42. Strober W, Fuss IJ, Blumberg RS (2002). The immunology of mucosal models of inflammation. Annu Rev Immunol 20: 495-549.
43. Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazalé T, Raupach B et al. (2005). Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun 73: 1452-1465.
44. Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W et al. (2007). Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS ONE 2 (12): e1308.
45. Wehkamp J, Harder J, Wehkamp K, Wehkamp-Von Meissner B, Schlee M, Enders C et al. (2004). NF-kB-and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 72: 5750-5758.
46. Welbourn CR, Young Y (1992). Endotoxin, septic shock and acute lung injury: neutrophils, macrophages and inflammatory mediators. Br J Surg 79: 998-1003.
47. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA (2007). Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 9: 804-816.